Arkadios Wealth Advisors’s Matinas BioPharma MTNB Stock Holding History

Arkadios Wealth Advisors’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-32,480	Closed	-$440K	–	896
2024 Q1	$440K	Hold	32,480	–	–	0.03%	408
2023 Q4	$351K	Buy	32,480 +4,500	+16%	+$50.8K	0.03%	466
2023 Q3	$182K	Hold	27,980	–	–	0.02%	624
2023 Q2	$504K	Hold	27,980	–	–	0.06%	305
2023 Q1	$658K	Hold	27,980	–	–	0.08%	249
2022 Q4	$700K	Hold	27,980	–	–	0.09%	228
2022 Q3	$890K	Hold	27,980	–	–	0.13%	171
2022 Q2	$1.1M	Hold	27,980	–	–	0.16%	161
2022 Q1	$1.13M	Hold	27,980	–	–	0.15%	169
2021 Q4	$1.41M	Hold	27,980	–	–	0.19%	130
2021 Q3	$1.82M	Buy	27,980 +20,980	+300%	+$905K	0.26%	96
2021 Q2	$271K	Buy	+7,000	New	+$301K	0.03%	467

Other funds holding MTNB

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AWMG

Alliance Wealth Management Group Flemington, New Jersey $514M AUM 16.05% 1-Year Est. Return

TCM

Towercrest Capital Management Newtown, Pennsylvania $717M AUM 15.39% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arkadios Wealth Advisors's MTNB Position: Q2 2024 in Review

Arkadios Wealth Advisors sold out of Matinas BioPharma (MTNB) in Q2 2024, closing a stake of 32,480 shares — an estimated $440K sold.

Arkadios Wealth Advisors first reported a position in MTNB in Q2 2021 and held it in 12 quarters. The position peaked at $1.82M in Q3 2021. 48 funds tracked by Wall St. Rank hold MTNB as of Q2 2024.

Arkadios Wealth Advisors reported no remaining Matinas BioPharma position as of Q2 2024 after selling out during the quarter.
Arkadios Wealth Advisors sold 32,480 Matinas BioPharma shares in Q2 2024, an estimated $440K.
Arkadios Wealth Advisors first reported a position in Matinas BioPharma in Q2 2021 and held it in 12 quarters.
Arkadios Wealth Advisors's Matinas BioPharma position peaked at $1.82M in Q3 2021.
48 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2024.

Based on Arkadios Wealth Advisors's 13F filing for Q2 2024, filed 29 Jul 2024.